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The serum amyloid A3 promoter-
driven luciferase reporter mice is a 
valuable tool to image early renal 
fibrosis development and shows 
the therapeutic effect of glucosyl-
hesperidin treatment
Thanutchaporn Kumrungsee  1, taishi Kariya1, Kotaro Hashimoto1, takayuki Koyano  2, 
nao Yazawa1, takao Hashimoto1, Yohei Sanada1, Makoto Matsuyama2, Yusuke Sotomaru3, 
Hiroaki Sakurai  4, fons A. J. van de Loo5 & noriyuki Yanaka1
Tubulointerstitial fibrosis is a progressive process affecting the kidneys, causing renal failure that 
can be life-threatening. Thus, renal fibrosis has become a serious concern in the ageing population; 
however, fibrotic development cannot be diagnosed early and assessed noninvasively in both patients 
and experimental animal models. Here, we found that serum amyloid A3 (Saa3) expression is a potent 
indicator of early renal fibrosis; we also established in vivo Saa3/C/EBPβ-promoter bioluminescence 
imaging as a sensitive and specific tool for early detection and visualization of tubulointerstitial fibrosis. 
Saa3 promoter activity is specifically upregulated in parallel with tumor necrosis factor α (TNF-α) and 
fibrotic marker collagen I in injured kidneys. C/EBPβ, upregulated in injured kidneys and expressed 
in tubular epithelial cells, is essential for the increased Saa3 promoter activity in response to TNF-
α, suggesting that C/EBPβ plays a crucial role in renal fibrosis development. Our model successfully 
enabled visualization of the suppressive effects of a citrus flavonoid derivative, glucosyl-hesperidin, on 
inflammation and fibrosis in kidney disease, indicating that this model could be widely used in exploring 
therapeutic agents for fibrotic diseases.
About 750 million people suffer from chronic kidney disease (CKD) with global deaths predicted to rise from 1.2 
million in 2016 to 3.1 million in 20401,2. CKD causes progressive decline in both kidney function and structure 
without obvious outward symptoms, making it difficult to diagnose until end stage where it is irreversible and 
requires dialysis or kidney transplantation to maintain patients’ lives, which is an economic burden for develop-
ing countries2–4. Thus, effective disease assessment at early stages is essential in order to improve diagnosis and 
prognosis and to provide prompt treatment before the onset of end-stage renal disease. Renal fibrosis, particularly 
tubulointerstitial fibrosis, is a hallmark of end-stage kidney disease5,6. Molecular mechanisms of tubulointerstitial 
fibrosis involve tubular epithelial cells, a primary target of renal injurious stimuli, being injured by intratubular 
hydrodynamic forces, such as tubular stretch induced by obstruction; which activates inflammatory and fibro-
genic signals5–7. Together with the alteration of tubular epithelial phenotype, these signals lead to activation of 
tubulointerstitial fibroblasts and myofibroblasts, resulting in deposition of extracellular matrix (ECM), such as 
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collagen in interstitial areas, finally leading to tubulointerstitial fibrosis. At the transcriptional level, in response 
to injuries, transcriptional factors that regulate expression of genes involved in fibrosis, such as α-smooth muscle 
actin (αSMA), are activated. In addition to myofibroblasts, recent studies have suggested that renal tubular epi-
thelial cells are an important initiator and mediator of tubulointerstitial fibrosis and attempted to isolate marker 
proteins in injured tubular epithelial cells to serve as indicators for early detection of tubulointerstitial fibrosis8,9.
In a few decades, in vivo imaging technologies have become essential for the basic sciences and for trans-
lational drug development because they provide an important opportunity for studying biological processes 
in living organisms in real time at a molecular level. Recently, imaging devices have been developed to gain 
high-resolution bioluminescence images of luciferase or fluorescence proteins and are applicable for studying not 
only tumorigenesis but also inflammatory diseases and other pathologies10,11. In our previous study, we success-
fully used a mouse serum amyloid A3 (Saa3) gene promoter-luciferase (luc) reporter to monitor inflammation 
in fat tissue of obese mice12. Saa3 is a member of the Saa family, which comprises of acute-phase proteins highly 
expressed under various inflammatory conditions and whose mRNA expression profiles in chronic inflammatory 
diseases, such as rheumatoid arthritis, atherosclerosis, and colitis, have been studied13–15. In the mouse Saa3 gene 
promoter region, there are three CCAAT/ enhancer binding protein β (C/EBPβ)-binding sites (−152, −107, and 
−77)12,13,16. C/EBPβ is transcriptionally activated by inflammatory stimuli, including inflammatory cytokines, 
such as interleukin-6 (IL-6), IL-1, and tumor necrosis factor α (TNF-α), and the possibility that C/EBPβ may play 
an important role in inflammatory signals during disease development has been explored12,13,17–19. In addition, 
there is an upregulation of the Saa family proteins in serum and kidney tissue of both patients and experimental 
animals having kidney disease20–25. Taken together, these observations indicate that C/EBPβ and its regulated Saa 
family of genes may represent an important target for assessing kidney injury and the Saa3-promoter reporter 
might be used in live animals for visualizing the injury in experimental kidney disease models and for monitoring 
therapeutic effects of functional food on the pathology of diseases.
Here, we report that in vivo Saa3/C/EBPβ-promoter bioluminescence imaging is a novel, sensitive, and specific 
approach for detecting and visualizing tubulointerstitial injury and fibrosis as well as monitoring the therapeu-
tic effect of functional food on kidney disease. In fact, our in vivo bioluminescence imaging model revealed a 
functional food, which shows preventive effect on kidney disease. Importantly, we also report here that C/EBPβ 
plays a crucial role in renal tubulointerstitial injury and fibrosis, possibly by driving the fibrotic marker Saa3. As 
C/EBPβ is likely to be an upstream regulator for tubulointerstitial fibrosis, our finding may open the door to the 
design of future therapeutic strategies or screening for novel therapeutic functional food by controlling the levels 
of expression of C/EBPβ.
Results
Upregulation of Saa3 promoter activity in adenine-induced kidney injury. To determine if the 
Saa3-promotor (−314/+50) reporter is useful for assessing kidney injury, we employed transgenic mice carrying 
the Saa3 promoter-luc chimeric gene. Since the transgenic mice showed high Saa3 promoter activity in kidney 
tissue under normal conditions (Supplementary Fig. S1a), it is logical to examine the luciferase activity based 
on Saa3 promoter activity during kidney disease development by in vivo imaging technique. In order to induce 
injury in kidney, mice were fed the adenine-containing diet for three weeks. We found that blood urea nitrogen 
(BUN) and plasma creatinine concentrations in the adenine group were significantly increased as compared to 
the control group (Fig. 1a,b). Pathological changes in the adenine-induced kidney were observed using hema-
toxylin-eosin (H&E) and Azan-Mallory (AZM) staining; deposition of 2,8-dihydroxyadenine (DHA) crystals in 
renal tubules (brown), expansion of interstitial ECM, and accumulation of collagen, which are typical patholo-
gies of tubulointerstitial fibrosis, were observed after three weeks, while abnormal tubular dilation and atrophy 
appeared after one week of the adenine diet (Supplementary Fig. S2). We further observed that Saa3 mRNA 
expression was greatly upregulated (13-fold, p < 0.05) in the kidney tissue of adenine-fed mice (Fig. 1c). Next, 
to employ the in vivo Saa3 promoter-luc model for monitoring the kidney injury, Saa3 promoter-luc mice were 
divided into two groups receiving the adenine diet or the control diet and subjected to in vivo bioluminescent 
analysis. Shortly after one week of feeding, in vivo bioluminescence imaging from the back of Saa3 promoter-luc 
mice showed that injured kidneys emitted a strong bioluminescent signal (from violet for least intense to red for 
most intense), while uninjured kidneys of the mice fed the control diet showed none or less bioluminescent sig-
nal (Fig. 1d). To confirm that the visualized Saa3 promoter activity or the bioluminescent signal was specifically 
generated from the injured kidneys, we opened up the belly of Saa3 promoter-luc mice that were fed the adenine 
diet or the control diet and subjected them to the in vivo bioluminescent analysis. As shown in Fig. 1e, a very 
intense bioluminescent signal was specifically observed from the adenine-induced injured kidney (the white 
arrow), and not from the adjacent organs, whereas the uninjured kidneys and the other organs of the mice that 
were fed the control diet showed no bioluminescent signal. This in vivo result is consistent with the ex vivo result 
demonstrating that the adenine-induced injured kidney tissue exhibited a higher Saa3 promoter activity (lucif-
erase activity) than the non-adenine-induced kidney tissue (3.5-fold, p < 0.01, Fig. 1f). In addition, upon ade-
nine induction, kidney tissue showed a higher Saa3 promoter activity than other organ tissues (Supplementary 
Fig. S1b). These results indicated that the bioluminescent signal observed in Saa3 promoter-luc mice specifically 
reflected kidney injury. To assess the correlation of Saa3 promoter activity with mRNA expressions of Saa3, a 
fibrotic marker (collagen I (ColI)), and an inflammatory marker (TNF-α) in the injured kidneys from the tissue 
lysate was subjected to qualitative RT-PCR analysis and Pearson’s correlation coefficient analysis. Saa3 mRNA 
expression levels in the injured kidneys actually exhibited a positive correlation with Saa3 promoter activity 
(r = 0.729, p < 0.05, Fig. 1g). Importantly, mRNA expression levels of ColI and TNF-α were positively correlated 
with Saa3 promoter activity (r = 0.997, p < 0.05; r = 0.991, p < 0.05, respectively; Supplementary Fig. S3a,b). In 
addition to these, a significant correlation between Saa3 promoter activity with transforming growth factor beta 
1 (TGF-β1) (r = 0.980, p < 0.05, Supplementary Fig. S3c) was found. These results suggested that an increase in 
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Saa3 promoter activity was possibly associated with tubulointerstitial fibrosis and inflammation occurring in 
adenine-induced kidney disease. In this study, one week of the adenine diet did not change BUN and plasma cre-
atinine concentration (Supplementary Fig. S4), and deposition of DHA crystals was not observed in renal tubules 
Figure 1. Bioluminescence imaging allows visualization of adenine-induce tubulointerstitial injury and 
fibrosis in Saa3 promoter-luc mice. (a–c) Wide-type mice were divided into two groups (n = 4) receiving the 
control diet (cont) or the adenine diet (adenine) for 3 weeks. (a) Plasma BUN and (b) creatinine levels were 
increased by the adenine diet (n = 4). (c) The relative Saa3 mRNA level in kidney tissues was determined by 
quantitative PCR and normalized to L19 mRNA level (n = 4). (d–k) Saa3 promoter-luc mice were divided 
into two groups (n = 4) receiving the control diet (cont) or the adenine diet (adenine) for one week. (d) In 
vivo bioluminescence imaging from the back of Saa3 promoter-luc mice that were fed the adenine diet shows 
a strong intensity of bioluminescent signal (from violet for least intense to red for most intense), reflecting 
kidney injury. (e) Exposure of mouse organs under in vivo bioluminescent analysis exhibited a very intense 
bioluminescent signal generated specifically from the injured kidney (the white arrow), and not from the 
adjacent organs of the mice that were fed the adenine diet. (f) Kidney tissues were isolated and subjected to the 
ex vivo luciferase activity assay to show enhancement of bioluminescent signal intensity induced by the adenine 
diet (n = 4). (g) The relative Saa3 mRNA expression level in kidney tissue was determined by quantitative PCR 
and normalized to L19 mRNA level (n = 4). Pearson’s correlation coefficient showed a positive correlation 
between luciferase activity (promoter activity) and Saa3 mRNA expression level in kidney tissue. (h–j) The 
treatment with allopurinol of Saa3 promoter-luc mice (n = 3) receiving the adenine diet for six weeks. (h) 
The in vivo bioluminescence imaging shows decreased signal intensity in the adenine-induced mouse treated 
with allopurinol, reflecting less severe injury in kidney, as compared with the adenine-induced mouse without 
allopurinol treatment. (i,j) Allopurinol decreased plasma BUN and creatinine levels in the adenine-induced 
mice (n = 3). All values are expressed as mean ± S.E. Student’s t-test, *p < 0.05, **p < 0.01.
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(Supplementary Fig. S2a). However, replacement of connective tissue began after only one week of the adenine 
diet (Supplementary Fig. S2b). Taken together, these results indicated a potential ability of the in vivo biolumines-
cence imaging from Saa3 promoter-luc mice to predict tubulointerstitial fibrosis at an early phase.
To verify the reliability of this Saa3 promoter-luc mouse model as a tool for monitoring kidney injury and 
tubulointerstitial fibrosis, we applied this model to assess the therapeutic effect of allopurinol, a xanthine dehy-
drogenase inhibitor as a positive control drug26, on adenine-induced kidney injury. As shown in Fig. 1h, there 
was no bioluminescent signal in the control group, reflecting uninjured kidney, but a strong signal intensity in 
the adenine group, indicating severely injured kidneys, and a decrease in the signal intensity in the adenine group 
treated with allopurinol, reflecting less severe injury of the kidney, due to the therapeutic effect of allopurinol. 
These in vivo bioluminescent results were confirmed by biochemistry results, in which plasma BUN and creati-
nine concentrations in the adenine group were significantly increased as compared to the control group but were 
significantly decreased by allopurinol treatment (Fig. 1i,j). Taken together, the Saa3 promoter-luc mouse model 
established in this study is a non-invasive and useful tool for visualizing progressive kidney injury and possibly 
predicting tubulointerstitial fibrosis in the early stage in live animals.
Upregulation of Saa3 promoter activity in a unilateral ureteral obstruction model. To confirm 
if the Saa3 promoter-luc mouse model can be used to detect acute tubulointerstitial injury and predict tubuloin-
terstitial fibrosis, we applied unilateral ureteral obstruction (UUO), that is an acute and well-established model 
of tubulointerstitial injury/fibrosis, in this study5. Saa3 promoter-luc mice were operated, and their left kidneys 
were ligated to obstruct the flow of urine, while their right kidneys were left unligated. Shortly after 3 days of the 
UUO operation, we subjected the mice to in vivo bioluminescent analysis and found that the ligated kidneys (left 
side indicated as “L” in Fig. 2a) showed stronger intensity of the bioluminescent signal than the unligated kidneys 
(right side indicated as “R” in Fig. 2a), while Saa3 promoter-luc mice with sham operation exhibited no biolumi-
nescent signal in both the kidneys (Supplementary Fig. S5). These results suggested that acute tubulointerstitial 
injury, specifically upregulated Saa3 promoter activity, and higher Saa3 promoter activity visualized in ligated kid-
neys indicated greater severity of tubulointerstitial injury than that in unligated kidneys and sham-operated kid-
neys. To confirm this, kidney tissues were isolated, lysed, and subjected to the ex vivo quantitative luciferase assay. 
As compared with the basal Saa3 promoter activity from uninjured kidneys (cont), Saa3 promoter activity was 
increased in parallel with greater severity of tubulointerstitial injury in unligated kidneys (R) and ligated kidneys 
(L), respectively (Fig. 2b). Notably, the bioluminescent signal and Saa3 promoter activity observed in unligated 
kidneys (R) shown in Fig. 2a,b is possibly from hyperfiltration of unligated kidneys, due to the ligation of the left 
kidney. Subsequently, the hyperfiltration of unligated kidneys might result in intratubular hydrodynamic forces 
triggering inflammatory and fibrogenic signals5, which, in turn, caused upregulation of Saa3 promoter activity. 
In fact, the unligated right kidneys showed higher mRNA expression level of ColI, αSMA, and TGFβ compared 
with kidneys from control mice (Supplementary Fig. S6). Next, we further assessed mRNA expressions of Saa3, 
fibrotic markers, and inflammatory markers by subjecting the tissues of sham-operated and ligated or UUO 
kidneys after three days of the operation to qRT-PCR analyses and found that increased mRNA expressions of 
Saa3, ColI, αSMA, TGF-β, TNF-α, and EGF-like module containing mucin-like hormone receptor1 (Emr1) were 
clearly seen in UUO kidneys than in sham-operated kidneys (Fig. 2c). Immunohistochemical analyses revealed 
that severe tubulointerstitial damage was present after seven days of the UUO operation (Fig. 2e), as reflected by 
a highly increased αSMA expression and reduction of E-Cad expression compared with those from three day 
UUO kidneys (Fig. 2d). However, Saa3 promoter activity as well as mRNA expression of Saa3, ColI, αSMA, and 
TNF-α was upregulated early in tubulointerstitial injury (three days). In the UUO kidneys after three days of the 
operation, dilated tubules were observed and αSMA-positive area was moderately increased (Supplementary 
Fig. S7). These observations suggest that the Saa3 promoter-luc mouse model can be used to detect tubulointer-
stitial injury and predict fibrosis in the early stage.
C/EBPβ plays a crucial role in controlling Saa3 promoter activity. In this study, we aimed to deter-
mine a possible role of the transcription factor, C/EBPβ in kidney injury and fibrosis by monitoring Saa3 pro-
moter activity. First, we examined if C/EBPβ is upregulated in injured kidneys by subjecting the tissue lysates of 
the adenine- and UUO-treated kidneys to qRT-PCR and western blot analyses. As shown in Fig. 3a,b, C/EBPβ 
mRNA and protein expressions were highly increased in both adenine-treated and ligated kidneys (L) com-
pared with uninjured kidneys in the control group (cont) and unligated kidneys (R). Taken together with the 
results demonstrating an upregulation of Saa3 mRNA expression and Saa3 promoter activity in the adenine- and 
UUO-treated kidneys (Figs 1 and 2), these results suggested a possible relationship between C/EBPβ and Saa3 
expression in kidney injury. To determine which cells are responsible for C/EBPβ expression in injured kidneys, 
serial sections of the adenine-treated kidneys were analyzed by immunohistochemical analysis. As shown in 
Fig. 3c, C/EBPβ localized specifically in tubular epithelial cells, confirmed by having the same localization with 
E-Cad, a specific surrogate marker of renal tubular epithelial cells27. Given this, we carried out experiments using 
human renal tubular epithelial cell line HK-2 to confirm direct regulation of the Saa3 promoter activity by C/
EBPβ. Upon transfection into HK-2 cells carrying Saa3 promoter-luc gene, overexpression of C/EBPβ remarkably 
increased Saa3 promoter activity, which was further enhanced by the addition of TNF-α, an inflammatory stimu-
lus reported to activate C/EBPβ12 (Fig. 3d). C/EBPβ-biding sites are located at −152, −107, and −77 bp upstream 
of the transcription start site in the Saa3 promoter (Fig. 3e)12,13,16. Thus, we constructed three Saa3 promoter 
mutants at those three binding sites and the wild-type (WT) Saa3 promoter (Fig. 3e) to determine whether these 
C/EBPβ-binding sites are important for Saa3 promoter regulation. After transfection into HK-2 cells, both the 
WT and mutant construct I (−77) exhibited a 2-fold increase in luciferase activity in response to TNF-α, while 
mutant constructs II (−107) and III (−152) abolished luciferase activity upon TNF-α treatment (Fig. 3f). These 
results strongly indicated that C/EBPβ played a crucial role in regulation of Saa3 promoter activity, specifically 
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Figure 2. Bioluminescence imaging allows early prediction of tubulointerstitial injury and fibrosis in Saa3 promoter-
luc mice under unilateral ureteral obstruction. (a–c) Saa3 promoter-luc mice were under unilateral ureteral 
obstruction (UUO) for 3 days (n = 4). Left ureters of the mice were ligated for three days (“L” represents left side 
and ligated kidneys), while right ureters were left without the ligation (“R” represents right side). (a) The in vivo 
bioluminescence imaging showed a stronger intensity of bioluminescent signal in the ligated kidneys (L) than in 
the unligated kidneys (R). (b) Kidney tissues were isolated and subjected to the ex vivo luciferase activity assay to 
show upregulation of Saa3 promoter activity in the ligated kidneys (L), as compared with the unligated kidneys (R) 
and control kidneys without the operation (cont) (n = 4). (c) mRNA levels of Saa3, ColI, TNF-α, TGFβ, αSMA and 
Emr1 in left kidney tissues of the sham (Cont) and UUO mice (UUO L) were analyzed by quantitative RT-PCR and 
normalized to L19 mRNA level (n = 5). (d,e) Wild-type mice were divided into two groups with sham operation or 
UUO operation. Mice were sacrificed at three or seven days after the operation. (d) and (e) Immunohistochemical 
staining shows expressions of E-Cad and αSMA in sham and UUO kidneys after three and seven days of the 
operation, respectively. αSMA protein is also expressed in the blood vessel and shown as a positive control by a star. 
Scale bar, 25 μm. All values are expressed as mean ± S.E. Student’s t-test, *p < 0.05, **p < 0.01.
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through the C/EBPβ-biding sites at −107 and −152 bp of the Saa3 promoter. To confirm this in vivo, we analyzed 
the correlation between Saa3 promoter activity and C/EBPβ mRNA level in the adenine-treated kidney tissue by 
using Pearson’s correlation coefficient analysis and found that there was a significant correlation between Saa3 
promoter activity and C/EBPβ mRNA level (r = 0.997, p < 0.05, Supplementary Fig. S8). In addition, C/EBPβ 
mRNA level was found to be significantly correlated with ColI mRNA level (r = 0.979, p < 0.05, Supplementary 
Fig. S8), suggesting a possible role of C/EBPβ in renal fibrosis. Taken with the previous results, the findings 
Figure 3. C/EBPβ is involved in regulating Saa3 promoter activity responsible for tubulointerstitial injury 
and fibrosis. (a) Wild-type (WT) mice were divided into two groups (n = 6) receiving the control diet (cont) 
or the adenine diet (adenine) for two weeks. The relative C/EBPβ mRNA expression level in kidney tissue 
was determined by quantitative PCR and normalized to L19 mRNA level (n = 4). Then, kidney tissues were 
isolated, lysed, and subjected to western blot analysis to determine C/EBPβ protein level (n = 2). (b) Left ureters 
of WT mice in the unilateral ureteral obstruction (UUO) group were ligated for three days (“L” represents left 
side), while right ureters were left without the ligation (“R” represents right side). The control group without 
the operation was used to compare with the UUO group. The relative C/EBPβ mRNA expression level in 
kidney tissue was determined by quantitative PCR and normalized to L19 mRNA level (n = 5). Then, kidney 
tissues were isolated, lysed, and subjected to western blot analysis to determine CEBP/β protein level (n = 2). 
(c) Immunohistochemical staining shows expressions of E-Cad and CEBP/β in kidney tissues from WT mice 
under the adenine diet for two weeks. (d) HK-2 cells were transiently transfected with constructs for Saa3-luc 
with pcDNA-C/EBPβ or empty vector. Two days after transfection, cells were treated with 10 ng/ml of TNF-α 
for 8 h, scraped and subjected to the luciferase assay. Data are means of triplicate experiments (n = 4). (e) 
Saa3 promoter was mutated and ligated upstream of the complete luciferase cDNA, generating mutant Saa3 
promoter-luciferase chimeric genes (mut I, mut II, and mut III), respectively. (f) HK-2 cells were treated with 
10 ng/ml of TNF-α for 8 h, followed by the luciferase assay. The data are from a single experiment carried 
out (n = 3) and are representative of two independent experiments. Full-length gels and blots are included in 
Supplementary Fig. S11.
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implied that Saa3 promoter-luc mouse model could be used to reflect C/EBPβ activity in driving tubulointer-
stitial injury and fibrosis. To explore the biological significance of Saa3 expression in tubular epithelial cells, we 
used the siRNA-mediated the human homolog serum amyloid A (SAA1) knockdown in HK-2 cells. The amount 
of reduced mRNA expression was assessed by quantitative RT-PCR (Supplementary Fig. S9). Silencing of the 
SAA1 RNAi gene resulted in a decreased interleukin-8 (IL-8) mRNA expression in HK-2 cells (Supplementary 
Fig. S9). Because renal tubular epithelial cells are studied to produce inflammatory mediators, such as cytokines 
and chemokines, and actively participate in acute inflammatory processes by effecting and directing leukocyte 
chemotaxis via the production of IL-828, these data suggest that SAA1 is actually involved in the early pathological 
process of kidney fibrosis and SAA1 serum levels might be useful assessing early stage human renal disease.
Application of Saa3 promoter-luc mouse model in searching for functional food preventing kid-
ney disease. Citrus flavonoids have been reported to have protective kidney functions, including prevention 
of renal crystal formation29. In this study, we decided to use Saa3 promoter-luc mouse model for monitoring the 
potential preventive effect of citrus flavonoids on adenine-induced kidney disease. Since preliminary studies with 
certain types of flavonoids revealed a possibility of glucosyl-hesperidin (G-Hes) in preventing kidney injury, we 
subjected G-Hes to the in vivo bioluminescence imaging model. Transgenic mice were divided into three groups: 
the control group receiving the control diet, the adenine group receiving the adenine diet, and the G-Hes receiv-
ing the G-Hes-mixed adenine diet for one week. Three days prior to the treatment, the G-Hes group received 
the G-Hes diet, while the control and adenine groups received the control diet. After one week of the treatment, 
we subjected all mice to in vivo bioluminescent analysis. As shown in Fig. 4a, in vivo bioluminescence imaging 
showed strong signal intensity in the adenine group, indicating severely injured kidneys, and a decrease in the sig-
nal intensity in the G-Hes group (Supplementary Fig. S10a), indicating less severe injury of the kidneys, possibly 
due to the therapeutic effect of G-Hes, while no bioluminescent signal was observed in uninjured kidney of the 
control group (cont) that confirmed the specificity of Saa3 promoter activity to the injury. This result strongly sug-
gested a preventive effect of G-Hes on adenine-induced kidney disease. To further confirm the preventive effect of 
G-Hes, after 3 weeks of the above treatment, all mice were sacrificed and subjected to further analyses. Figure 4b 
shows abnormal, ivory-white appearance of the adenine-treated kidney possibly due to DHA crystal accumula-
tion, while the G-Hes treatment group showed usual appearance of kidney, suggesting the possibility of G-Hes in 
preventing DHA crystal formation. To observe morphological changes, the kidneys were sectioned and stained 
with Azan-Mallory stain. It appeared that G-Hes suppressed deposition of DHA crystals in renal tubules (brown), 
expansion of ECM, tubular dilation and atrophy, and tubulointerstitial fibrosis (blue), which were greatly present 
in the adenine group (Fig. 4c and Supplementary Fig. S10b,c). Consistent with histochemical staining results, 
G-Hes showed renal-protective effects by the significant reduction of plasma BUN and creatinine concentrations 
(Fig. 4d,e). Since G-Hes showed a potential suppression of DHA crystal formation in kidneys, we were interested 
in investigating the inhibitory effect of dietary G-Hes on activity of xanthine oxidoreductase (XOR), an enzyme 
responsible for conversion of adenine to DHA26. As shown in Fig. 4f, G-Hes suppressed XOR activity in vivo, indi-
cated by the significant reduction of plasma levels of uric acid, a metabolic product of XOR, suggesting a possible 
renal protective effect of G-Hes through suppression of DHA crystal formation. To ensure that a reduction in 
plasma uric acid levels was due to the decreased activity of XOR by G-Hes and not by uricase, the uricase inhibitor, 
potassium oxonate, was applied during XOR activity assessment. Given that G-Hes is hydrolyzed to hesperetin by 
gut flora prior to being absorbed, we further confirmed the inhibitory effect of hesperetin on in vitro XOR activity 
from milk (IC50 value was 10.6 μM). Qualitative RT-PCR analysis revealed that G-Hes treatment downregulated 
mRNA expressions of Saa3, C/EBPβ, ColI, αSMA, and TNF-α (Fig. 4g–k), indicating a possible role of G-Hes in 
suppressing inflammation and fibrosis in adenine-induced kidney disease. Taken together, the results suggested 
that G-Hes exerts its renal preventive effect through suppression of accumulation of DHA crystals in tubules via 
inhibition of XOR activity, thereby preventing tubular injury subsequent to reduction of inflammation, lead-
ing to prevention of further tubular injury and fibrosis in the kidneys. Notably, by exploiting the specificity of 
Saa3-promoter activity, this preventive effect could be visualized by bioluminescence imaging of live mice.
Discussion
Scientific testing on animals has become a moral and social point of contention. In recent years, efforts have 
been made to reduce the number of experimental animals and to establish new non-invasive methods. In vivo 
bioluminescence imaging as a potent non-invasive assessment has been applied in various disease models, such 
as inflammation diseases and cancer metastasis11,12,30–32. However, until this point, this technology has not been 
utilized in kidney disease research. Examination by non-invasive imaging for renal fibrosis in both human and 
experimental animals, in particular, is nonexistent. Generally, tubulointerstitial fibrosis, a predictor of the pro-
gression of end-stage renal disease33, in patients is commonly assessed by biopsy and histological analysis5,6,33. 
Similarly, in experimental animals, analysis of tubulointerstitial fibrosis is often done by histochemical and/or 
gene and protein expression analyses, which require tissue or organ harvesting after sacrificing the animal; there-
fore, disease progression or therapeutic response in the same animal over time cannot be observed. To overcome 
these limitations, here we established and demonstrated that in vivo Saa3/C/EBPβ-promoter bioluminescence 
imaging is a sensitive and specific tool for detecting and visualizing tubulointerstitial injury in real time in live 
animals from both primary kidney disease models, adenine-derived, and UUO models. Moreover, this novel bio-
luminescence imaging has an advantage of early prediction of tubulointerstitial fibrosis, which cannot be detected 
or clearly distinguished by the typical and traditional histological analysis or blood markers such as BUN and 
creatinine at an early phase.
C/EBPβ is a transcription factor of various genes including Saa, αSMA, and Col I12,13,17,18,34–36. C/EBPβ regu-
lates expression of its target genes by binding to its binding sites in the promoter region of these genes subsequent 
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Figure 4. Bioluminescence imaging of Saa3 promoter-luc mice allows monitoring the response to glucosyl-
hesperidin therapy in adenine-induced kidney disease model. (a) The treatment of glucosyl-hesperidin (G-Hes) 
given to Saa3 promoter-luc mice receiving the adenine diet for one week. The in vivo bioluminescence imaging 
shows decreased signal intensity in the adenine-induced mouse treated with G-Hes, reflecting less severe injury 
in kidney, as compared with the adenine-induced mouse without G-Hes treatment. (b–e) Wild-type mice 
were divided into two groups (n = 6) receiving the adenine diet (adenine) or the G-Hes-mixed adenine diet 
(adenine + G-Hes) for three weeks. (b) Appearance of kidneys in both groups. (c) Kidneys were sectioned and 
stained with Azan-Mallory to show morphological changes. (d) Plasma BUN and (e) creatinine levels were 
suppressed by the G-Hes treatment (n = 6). (f) G-Hes treatment reduced plasma uric acid levels, exhibiting the 
inhibition of endogenous xanthine oxidoreductase (XOR) activity, (n = 5). (g–k) The relative mRNA level of 
Saa3, CEBP/β, ColI, αSMA, and TNF-α, respectively, in kidney tissues of mice from the experiment in (b–e)
was determined by quantitative PCR and normalized to L19 mRNA level (n = 6). All values are expressed as 
mean ± S.E. Student’s t-test, *p < 0.05, **p < 0.01.
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to gene transcription. Recently, C/EBPβ has been reported to play a crucial role in chronic inflammatory diseases, 
such as rheumatoid arthritis13,16 and obesity12. Based on these findings, researchers have designed lentiviruses car-
rying Saa3/C/EBPβ-promoter reporter gene and used them as a sensitive tool for assessing arthritis and chronic 
inflammatory state in experimental animals12,13. In addition to involvement in chronic inflammatory diseases, 
recent emerging evidence has suggested a crucial rule of C/EBPβ in fibrosis17,18,35,36. In lung and liver fibrosis, 
its mechanism of action works by controlling transcription of αSMA and ColI genes and regulating fibroblast 
activation and myofibroblast differentiation via the TGF-β pathway. C/EBPβ-deleted mice exhibited a decrease 
in αSMA and ColI mRNA and protein levels and suppression of TGF-β-induced fibroblast differentiation into 
myofibroblasts subsequent to attenuation of ECM accumulation and fibrosis17,18,35–37. In renal injury and disease, 
there is a consensus that the transformation of fibroblasts to myofibroblasts plays a pathological role in inter-
stitial ECM accumulation during progressive tubulointerstitial fibrosis as assessed by upregulated expression 
of αSMA and other related ECM proteins5,6,33,38. Although the origin of interstitial myofibroblasts during renal 
fibrosis is controversial, TGF-β1 is a key mediator activating various cells, such as tubular epithelial cells, resident 
fibroblasts, and bone marrow–derived mesenchymal stem cells whereby they lose their normal phenotypes and 
acquire a myofibroblast phenotype, accelerating matrix synthesis in renal fibrosis33,38,39. In our study, we found 
that TGF-β1 mRNA expression level was positively correlated with Saa3 promoter activity. This suggests that the 
increased bioluminescent signal intensity observed in Saa3 promoter-luc mice reflected differentiation and acti-
vation of myofibroblasts in tubulointerstitial fibrosis.
In this study, Saa3 gene promoter activity was applied to predict tubulointerstitial fibrosis in both chronic 
and acute renal injuries. Thus, the pathological relationship between Saa3 and kidney disease and fibrosis should 
be discussed. Recent studies coincidentally reported the upregulation of members of the Saa family in plasma 
and kidney tissues of patients and experimental animals having kidney disease20–25. Not solely in the kidney, 
Saa was also found to play a role in fibrosis in other organs, including the lung, pancreas, and liver, in which 
Saa3-deficient mice exhibited markedly reduced ECM and fibrosis and a positive correlation between Saa expres-
sion with fibrotic markers and fibrotic severity was observed20,40,41. Although molecular mechanisms of Saa in 
fibrosis development have been unclear, recent studies suggest its possible association with inflammatory-related 
pathways. Saa3 has been reported to be an endogenous ligand for toll-like receptor 4 (TLR4), a receptor recently 
found to be implicated in inflammation and fibrosis42,43. Thus, it is possible that Saa3 may exert its fibrotic func-
tion through activation of the TLR4 signaling pathway. In response to injury or inflammation, Saa is highly syn-
thesized in local tissue21,44–46. In diabetic kidney disease (DKD), Saa was found to be expressed throughout the 
kidney and highly deposited in tubulointerstitial fibrotic areas in kidney tissues of both the patients and exper-
imental animals21. Under diabetes-like conditions (exposure to advanced glycation products (AGE)), Saa and 
inflammatory mediators, such as C-X-C motif chemokine ligand 5 (Cxcl5), C-C motif chemokine ligand 2 (Ccl2), 
and C-C motif chemokine ligand 5 (Ccl5) were significantly upregulated in renal podocytes47. Notably, knocking 
out Saa3 significantly inhibited AGE-induced expressions of Cxcl5, Ccl2, and Ccl5 in podocytes, while exogenous 
addition of recombinant Saa protein upregulated Saa3 itself and inflammatory mediators associated with nuclear 
factor-κB (NF-κB) activation21,47. Taken together with the notion that Cxcl5, Ccl2, and Ccl5 are chemoattract-
ants, these results indicate that Saa acted in a chemoattractive manner to modulate immune cell recruitment in 
injured or inflammatory sites in the kidney. Interestingly, some studies demonstrated that Saa was a connector 
binding ECM and immune cells, such as neutrophils, monocytes, T cells, and mast cells, providing cross talk 
between these cells and the accumulation of immune cells in inflammatory sites44,48. In the kidney, accumulation 
of immune cells and Saa in parallel with upregulation of TGF-β1 and αSMA were found in interstitial fibrotic 
areas, leading to an assumption that the presence of immune cells and Saa enhanced renal fibrosis44. More recent 
works examined an important role of macrophage recruitment during the development of renal fibrosis49,50. It 
showed that the recruited macrophages were mainly M1 macrophages at early stage (three days after the UUO 
operation) and then were shortly polarized into M2 macrophages, which released high levels of TGF-β1 to pro-
mote renal fibrosis50. This work is consistent with previous studies suggesting that TGF-β1 was a key mediator, 
controlling the phenotypic transition of resident renal cells into myofibroblasts, leading to fibrosis33,38,39. Although 
these observations suggest the involvement of Saa3 in the renal fibrotic process via inflammatory-related path-
ways, further experiments are needed to clarify the causal relationship between bioluminescent signal visualized 
in Saa3 promoter-luc mice and immune cell recruitment.
Finally, we applied Saa3 promoter-luc mice for the in vivo non-invasive exploration of food factors prevent-
ing kidney disease in the adenine-induced kidney disease model. We found that G-Hes effectively prevented 
renal inflammation and fibrosis, which accompanied inhibition of DHA crystal deposition in renal tubules. We 
also found the inhibitory effect of its hydrolyzed form, hesperetin, on XOR activity in vitro. As XOR is a critical 
enzyme, catalyzing the oxidation of hypoxanthine to uric acid51, we can expect that G-Hes would be a food factor 
preventing hyperuricemia with excess uric acid in the blood. This study provides a novel approach to investigate 
effects of functional food by visualizing bioluminescent signal in Saa3 promoter-luc mice. As described above, 
Saa3 is highly expressed in tubulointerstitial fibrotic areas in kidney tissues of mouse DKD models, whereas pre-
vious reports have demonstrated that Saa3 facilitated pulmonary metastasis through stimulating NF-κB/TLR4 
signaling pathways43,52. Taken together with these observations, Saa3 promoter-luc mouse model can be widely 
applied as an in vivo non-invasive model in exploring compounds or food factors for preventing not only DKD 
but also other diseases, such as cancer metastasis.
Materials and Methods
Establishment of Saa3 promoter-luc chimeric mice. Saa3/C/EBPβ-promoter transgenic mouse car-
rying mouse Saa3 promoter region (−314/+50) upstream of the complete luciferase cDNA was generated as 
described previously12,13,16. In this experiment, heterozygous mice harboring the transgene which were back-
crossed at least five times with purebred C57BL/6J mice (Charles River Japan, Kanagawa, Japan), and their control 
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littermates were used. Male CD-1 (ICR) mice (four weeks old) were from Charles River Japan. Mice were housed 
in groups of two or three in metal cages maintained at 24 °C with a 12-h light and dark cycle (lights on, 8:00 a.m. 
to 8:00 p.m.). MF solid chow (Oriental Yeast, Tokyo, Japan) and deionized water were provided ad libitum. The 
animal study was approved by the Hiroshima University Animal Committee (Permit Number: C13-3 and C18-2), 
and the mice were maintained in accordance with the Hiroshima University Guidelines for the Care and Use of 
Laboratory Animals.
Adenine-induced and UUO kidney injury experiments. Male C57BL/6J mice (eight weeks old, 
Charles River Japan) as WT mice and Saa3 promoter-luc mice (5-8 weeks old, established in this study) were 
housed in groups of two or three in metal cages under the conditions described above. The control diet used in 
all experiments was composed of the following components (g/kg diet): α-cornstarch, 402; casein, 200; sucrose, 
200; corn oil, 100; cellulose, 50; AIN-93G mineral mixture, 35; AIN-93 vitamin mixture, 10; and L-cystine, 3, as 
described previously53.
For the adenine-induced kidney injury experiment, the adenine diet was composed of the control diet mixed 
with adenine (FUJIFILM Wako, Osaka, Japan) in a dose of 2 g adenine/kg diet (0.2% w/w). This adenine dose 
was chosen because it showed a survival rate of 100% with the renal injury phenotypes reported previously26. The 
G-Hes diet was composed of the control diet mixed with G-Hes (Hayashibara, Okayama, Japan) (3% w/w), while 
the G-Hes-mixed adenine diet was composed of the adenine diet mixed with G-Hes (3% w/w). Both WT mice 
and Saa3 promoter-luc mice were randomly divided into the control group receiving the control diet, the adenine 
group receiving the adenine diet, and the G-Hes group receiving G-Hes-mixed adenine diet for one, two, or three 
weeks. In the G-Hes group, mice were fed the G-Hes diet for 3 days before the start of the adenine treatment. For 
allopurinol experiment, the allopurinol group was given allopurinol (25 mg/kg/day; Sigma, St. Louis, MO) in the 
drinking water from 2 weeks after the start of the adenine treatment until end of the experiment (six weeks). At 
the end of each experiment, mice were sacrificed, and organs and blood were harvested. The n for each experi-
mental group is defined within the figure legends.
For the UUO kidney injury experiment, WT mice and Saa3 promoter-luc mice were randomly divided into the 
UUO group or the sham group, and their left ureters were ligated with 6-G silk sutures, as previously described50,54. 
For sham operation, mice were treated the same way as UUO mice, except the ligation. After surgery, mice were 
fed the control diet and then sacrificed at three or seven days as mentioned in the legends of figures.
Plasmid construction, cell culture, and DNA transfection. Mouse Saa3 promoter region (−314/+50) 
was ligated upstream of the luciferase cDNA in pGEM3 (Promega, Madison, WI, USA), generating pSaa3-Luc. 
pSaa3-Luc was digested with both EcoRI and NotI, and the resulting DNA fragment containing the mouse Saa3 
promoter region (−314/+50) and luciferase cDNA (Saa3-Luc) was ligated into EcoRI and NotI sites of the pMX 
vector. Site-directed mutagenesis was performed using PrimeSTAR HS DNA Polymerase (TaKaRa Bio) as 
described previously12. The mutation was confirmed by DNA sequencing analysis. C/EBPβ cDNA was amplified 
using a PCR primer set (5′-CCGCGTTCATGCACCGCCTG-3′ and 5′-ACCCGCGCCGCGCTAGCAGT-3′) and 
subcloned into pcDNA3.1, which generated pcDNA-C/EBPβ. The human proximal tubular cell line HK-2 was 
cultured in a maintenance medium (10% fetal bovine serum, 100 units/ml penicillin and 100 μg/ml streptomycin 
in Dulbecco’s modified medium with low glucose) at 37 °C in 5% CO2/95% humidified air. DNA transfections 
were performed using GeneJuice Transfection Reagent (Merck Millipore, Billerica, MA) according to the man-
ufacturer’s instructions. After DNA transfection into HK-2 cells, these cells were stimulated with 10 ng/ml of 
mouse recombinant tumor necrosis factor-α (R&D system, Minneapolis, MN) for 24 h.
In vivo bioluminescence imaging analysis. Male Saa3 promoter-luc mice were injected intraperitoneally 
with D-luciferin (150 mg/kg body weight, Promega) and then anesthetized with pentobarbital sodium (Kyoritsu 
Seiyaku, Tokyo, Japan). After five min, Saa3-luc mice were placed in a prone position on the plate and imaged 
for 1 min with the camera set at the highest sensitivity level by NightOWL II Imaging Systems LB983 (Berthold 
Technologies, Bad Wildbad, Germany), except the mice shown in Fig. 1e (they were placed in a supine position). 
Photons emitted from tissues were analyzed using Indigo in vivo image software (Berthold). Signal intensity was 
quantified as the sum of all detected photon counts per second and presented as count/sec (cps). For any given 
analysis, all images were adjusted to the same scale of minimum and maximum luminescent intensity.
Ex vivo quantitative luciferase assay. Tissues obtained from Saa3 promoter-luc mice were homogenized 
in the lysis buffer (1% Triton-X 100, 2 mM DTT, 10% glycerol, and 25 mM Tris-HCl pH 7.5), followed by centrif-
ugation at 12,000 rpm, 4 °C, for 10 min and supernatant collection. For cell lysate, the cells were lysed in ice-cold 
lysis buffer. After sonication, cell lysate was centrifuged at 12,000 rpm and supernatant was collected. Luciferase 
activity was quantified using the luciferase assay kit (Toyo Inki, Japan) and a luminometer (Turner Model TD-20), 
expressed as relative light units normalized to total protein concentration of the cell or tissue extracts.
RT-PCR analyses. Total RNAs were isolated from kidney using RNeasy lipid tissue kit (Qiagen Sciences, 
Germantown, MD). The reverse transcriptase reaction was carried out with 1 μg total RNA as a template to syn-
thesize cDNA using ReverTra Ace (TOYOBO, Osaka, Japan) and random hexamers (TaKaRa Bio, Kyoto, Japan), 
according to the manufacturer’s instructions. For semi-quantitative PCR analysis, cDNA and primers were added 
to the GoTaq Master Mix (Promega) to give a total reaction volume of 20 µl. Reactions were sampled after 28 and 
30 cycles under different PCR conditions, to monitor product accumulation. For quantitative PCR analysis, cDNA 
and primers were added to the THUNDERBIRD SYBR qPCR Mix (TOYOBO), to give a total reaction volume of 
20 µl. PCR reactions were then performed using StepOnePlusTM (Applied Biosystems, Foster City, CA). Conditions 
were set to the following parameters: 2 min at 95 °C, followed by 40 cycles each of 15 s at 95 °C and 1 min at 
60 °C. The primers used for PCR analyses were as follows: Saa3, F, 5′-AAGGGTCTAGAGACATGTGG-3′, and R, 
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5′- ACTTCTGAACAGCCTCTCTG -3′; TNF-α, F, 5′-CCGAT GGGTTGTACCTTGTC-3′, and R, 5′-CGGACTC 
CGCAAAGTCTAAG-3′; αSMA, F, 5′-GGCTCTGGGCTCTGTA-3′, and R, 5′-CTCTTGCTCTGGGCT 
TCATC-3′; Col1, F, 5′-CCCAAGGAAAAGAAGC-3′, and R, 5′-ACATTAGGCGCAGGAAGGTCA-3′; L19, F, 5′-GGC 
ATAGGGAAGAGGAAGG-3′, and R, 5′-GGATGTGCTCCATGAGGATGC-3′; C/EBPβ, F, 5′-ACAAGCTGAG 
CGACGGTAC-3′, and R, 5′-ACAGCTGCTCCACCT TCTTC-3′.
Immunohistochemical analysis. Kidney tissues were fixed in 4% paraformaldehyde. Paraffin sections of 
4 µm were stained with H&E and Azan-Mallory stain. For immunofluorescence staining in Fig. 2d,e (three or 
seven days of UUO) and Fig. 3c (two weeks of the adenine treatment) frozen kidneys were sliced with 5-µm thick-
ness. The slices were fixed with acetone or 4% paraformaldehyde. After blocking in 5% donkey serum for 30 min 
at room temperature, slices were incubated with primary antibody, followed by Alexa Fluor labeled (Molecular 
probe) secondary antibody. The images were captured by confocal microscopy (FV2000, Olympus) and were pro-
cessed by Olympus fluoview ver.4.0. Antibodies of αSMA (Cell Signaling, 1A4, 48939), E-Cad (Abcam, DECMA-
1, ab11512), and CEBP/β (c-7962; Santa Cruz Biotechnology) were used.
Western blot analysis. Kidney tissues were homogenized in the lysis buffer (150 mM NaCl, 1% Nonidet 
P-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 7.4) followed by centrifugation at 12,000 rpm, 
4 °C, for 10 min and supernatant collection. Protein concentration of the supernatant was determined using the 
Bio-Rad protein assay kit (Bio-Rad) with BSA as a standard. 20 μg (protein equivalents) of the supernatant was 
resolved by SDS-PAGE, transferred onto a polyvinylidene difluoride (PVDF) membranes and immunoblotted 
with anti-CEBP/β (Santa Cruz Biotechnology) antibody.
Plasma BUN and creatinine analysis. BUN and creatinine were determined using a Beckman Coulter 
AU480 analyser (Beckman Coulter, Krefeld, Germany), which is an automated chemistry instrument for turbi-
dimetric, spectro-photometric, and ion-selective electrode measurements. Briefly, 200 μL plasma was used to 
measure these parameters according to the manufacturer’s protocol.
XOR activity analysis. WT mice were randomly divided into the control group or the G-Hes group. Before 
starting the experiment, the G-Hes group was treated with G-Hes (500 mg/kg body weight) in saline solution by 
a single oral administration for 2 h, while the control group was treated with saline solution. After 2 h, all mice 
were treated with the uricase inhibitor, potassium oxonate (250 mg/kg i.p., FUJIFILM Wako)55 in saline solu-
tion. Blood samples (100 μl each) were collected at 0, 0.5, 1, and 2 h after potassium oxonate injection by cutting 
the tail tip. Prior to G-Hes treatment, blood was also collected as the basal urate level. Plasma was obtained by 
centrifugation at 3000 rpm, for 10 min, and at 4 °C. Plasma urate levels were determined by high-performance 
liquid chromatography (HPLC) using a Cosmosil 5C18-PAQ (4.6 × 250 mm; Nacalai Tesque, Kyoto, Japan) with 
an isocratic elution of 20 mM phosphate buffer (pH 2.5) at a flow rate of 0.5 ml/min, a temperature of 30 °C, and 
a monitored wavelength of 290 nm.
Statistical analyses. Values were presented as means ± S.E. Statistical significance was determined by 
unpaired Student’s t test. For all tests, the results with p < 0.05 were considered statistically significant.
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